An observational study in Atrial Tachycardia, Stroke and Mortality, sponsored by Evangelical Hospital Düsseldorf. Active, not recruiting at 5 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-20.
Sponsored by Evangelical Hospital Düsseldorf · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 356 studies in Stroke with a site in Germany — 51 open to participants now, 66 under way, 8 of them phase 3. Stroke · Germany.
Among the 356 studies in Stroke with a site in Germany, this one is the 31st largest by planned enrollment of the 133 observational ones that give a count, is one of 11 that started in 2024, is one of 133 observational ones, reaches primary completion later than 17 of the 65 other live ones, and was the 345th registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →51 of the 356 studies in Stroke with a site in Germany are open now. Recruiting first, the newest first:
Hospital Universitari Vall d'Hebron Research Institute · Sites in Germany, Belgium, Italy and 3 more countries
Ages 18+
Charite University, Berlin, Germany · Sites in Germany
Giuseppe Tarantini · Sites in Germany
Ages 18–65
Dr. Yaroslav Winter · Sites in Germany, Czechia, Italy and 1 more country
Johannes Dorst · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
356 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 43 · Phase 3 62 · Phase 4 17
First in 1994; this study’s year is marked. 11 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 150 across 1,971 observational studies indexed under Stroke.
Median enrollment 200 across the 222 interventional studies, 368 across the 133 observational. Of the 242 that completed or were terminated, 52 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
125 of 356 have an industry lead sponsor. The 10 most frequent:
Evangelical Hospital Düsseldorf is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Evangelical Hospital Düsseldorf has 1 study filed under Stroke — fewer than ten, so there is no comparison to draw.
18 of the studies in Stroke with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05691244Phase 3Pharmazz, Inc.Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke | 2027-09 |
| NCT07357285iVascular S.L.U.Safety and Efficacy Evaluation of the iNstroke 4F Thromboaspiration Catheter in Patients With Acute Ischaemic Stroke Due to Primary Distal Medium Vessel Occlusions (DMVO) | 2026-11 |
| NCT07885189University Hospital TuebingenLong-Term Cognitive Recovery After Arteria Cerebri Media Ischemia: A Digital Assessment Using the TuCAN-App | 2026-11 |
| NCT06121336Ludwig-Maximilians - University of MunichPRecisiOn Medicine In StrokE: Evolution of Plasma Brain-Derived Tau in Acute Stroke | 2026-12-31 |
| NCT07299994Sigmund Freud PrivatUniversitatEfficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease | 2026-12-31 |
Add all 18 to your calendar (.ics) → With an account.
Among the 356 studies in Stroke with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim is to analyze long-term outcomes in a multicenter observational registry including patients undergoing atrial tachycardia rhythm control.
Patients undergoing atrial tachycardia rhythm control
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients undergoing atrial tachycardia rhythm control
Exclusion Criteria:
Follow-up \<30 days after atrial tachycardia rhythm control
Patients undergoing catheter ablation and/or electrocardioversion for atrial tachycardia
Mortality, stroke and cardiovascular hospitalization
Time frame: From AT rhythm control through study completion, an average of 2 years
Plan to share: Undecided
Started Jan 2024 (actual). Primary completion is estimated for Jan 2026, 24 months after the start.
Of 838 non-industry observational studies under Stroke, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 92. This study's planned 24 months is below that.
Counting every sponsor, half of 900 studies reached it within 40 months; a quarter within 18 and three quarters within 85.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Evangelical Hospital Düsseldorf